Available since January 2005, AlloMap is used to identify those with a low probability of rejection.

XDx received a $12.5 million senior secured multidraw term loan facility from GE Capital, Healthcare Financial Services. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared noninvasive AlloMap® Molecular Expression Testing and pursue the development of other gene expression-based tests for immune-mediated inflammatory diseases.

AlloMap is used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate-to-severe acute cellular rejection at the time of testing. It received FDA sanction in August 2008, has been available since January 2005 as a laboratory-developed test performed in XDx’ CLIA-certified lab, and reportedly been ordered by more than 50 U.S. transplant centers.

AlloMap Testing assays the RNA levels of 11 rejection biomarker genes and nine control genes with a blood test. This composite score is an integer ranging from 0 to 40 and discriminates between the absence or presence of moderate-to-severe acute cellular rejection. The AlloMap Test may be used for stable patients aged 15 years or older at any time after the second month post-transplant.

XDx is currently developing tests for use in kidney transplants. It is also reportedly working on diagnostics for Crohn disease, lupus, multiple sclerosis, rheumatoid arthritis, and Sjögren syndrome.

Previous articleArena Reduces Staff by 25% in Wake of Delayed Obesity Therapy Approval
Next articleBioTime Buys Assets from Cell Targeting to Boost Its Regenerative Medicine Focus